AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03727737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial magnetic Stimulation
Description: RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
Study NCT04340999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction studies and Quantitative EMG ( MUNE and IPA)
Description: Nerve Conduction Studies: Electrophysiological method that tests the presence/absence of peripheral neuropathy.~MUNE: Electrophysiological technique that assess number of motor units. IPA: Electrophysiological method that assess interference pattern and hence, borderline cases of neuropathy/ myopathy
Study NCT04392102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-2306(Niraparib）
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Study NCT04801719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK
Description: Randomised patients in selected arm received endoluminal RFA by 8F catheter (Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK) before stenting procedure. Repeated ablations were processed through stenotic areas of bile ducts (10W, 90-120s, Rita 1500, Angiodynamics Ltd), all drained biliary tracts were used for introducing catheter and performance of ablation. Ablation procedure was followed with uncovered self-expandable metal stent insertion.
Study NCT01758419 — intervention group
Intervention type: RADIATION
Intervention: Thallium-201 Myocardial Perfusion Study
Description: One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
Study NCT05187858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP3794
Description: LNP3794 capsules administered orally once daily
Study NCT00502307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib (AV-951)
Description: solid oral dosage form taken daily for three weeks per one month cycle
Study NCT00502307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: solid oral capsule containing excipients dosed daily for three weeks per month
Study NCT01022684 — intervention group
Intervention type: OTHER
Intervention: Cross section study
Description: This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
Study NCT04221126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMFI
Description: Tixel rapidly transfer thermal energy by a metallic pyramid tip that enable skin contact through integrated pulsed movements. The rapid heating dehydrates he epidermis and superficial dermis and creates micropores with no coagulative damage of surronding tissue.
Study NCT03445130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavandula Angustifolia oil (LO)
Description: two drops on the inside of an oxygen face mask for 15 minutes.
Study NCT03445130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Michelia Alba Leaf oil (MA)
Description: two drops on the inside of an oxygen face mask for 15 minutes.
Study NCT03445130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Almond oil (AO)
Description: two drops on the inside of an oxygen face mask for 15 minutes.
Study NCT03445130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: two drops on the inside of an oxygen face mask for 15 minutes.
Study NCT03412318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twisted file
Description: Use of twisted file during cleaning and shaping of root canals
Study NCT03412318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mpro
Description: Use of Mpro during cleaning and shaping of root canals
Study NCT01027299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Optimised temporary biventricular pacing.
Study NCT02537314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzocaine
Description: 0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
Study NCT02537314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
Study NCT03105700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.
Study NCT00793819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silodosin
Description: α1-adrenergic antagonist
Study NCT00793819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: silodosin
Description: α1-adrenergic antagonist
Study NCT02390115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastic tape application in shoulder
Study NCT02390115 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Elastic tape application in shoulder
Study NCT03009513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin+Glimepiride
Study NCT01420718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
Study NCT04221126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALA cream
Description: ALA compounded in a cream
Study NCT04221126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA cream
Description: ALA compounded in a cream
Study NCT04221126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALA gel
Description: ALA compounded in a gel
Study NCT04004533 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Description: At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
Study NCT05394584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy
Description: Cognitive stimulation therapy is a non-pharmacological intervention for people with dementia at mild to moderate stages. Group cognitive stimulation therapy is a 14-session intervention delivered twice every week for 7 weeks. In each session, mentally stimulating activities are conducted around a specific themed, such as current affairs, word association, categorising objects, and number game. Each group consists of eight people with similar levels of cognitive impairment, facilitated by two group leaders who lead the activities according to 18 key principles of the therapy, including new associations, opinions rather than facts, implicit learning, and person-centred.
Study NCT02506296 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DPPIV inhibitor -
Description: Mixed Meal Tolerance Test with or without a DPPIV inhibitor
Study NCT02506296 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous glucose monitoring system.
Description: participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
Study NCT01887249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Study NCT01887249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study NCT01420718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iRoot BP
Description: Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
Study NCT01494246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic mail
Description: Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
Study NCT04221126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA gel
Description: ALA compounded in a gel
Study NCT04503356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI as a standalone procedure
Description: It uses a single, self-sealing clear corneal incision with ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System as a standalone procedure.
Study NCT04503356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI combined with cataract surgery
Description: Phacoemulsification with intraocular lens implantation is performed. Then, ab-interno transluminal 360 degree viscodilation of Schlemm's canal followed by up to 360 degree trabeculotomy performed using the OMNI Surgical System.
Study NCT00947596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atropine sulfate
Description: dry powder for inhalation
Study NCT01887249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Study NCT01887249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Study NCT04330911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Exercise loading is determined by increasing the heart rate. This loading calculated by Karvonen formulas (maximum %80 of Heart Rate)
Study NCT01887249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Study NCT01887249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Study NCT01694576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel and nedaplatin
Description: Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
Study NCT03698513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: BMS-986177 capsule
Study NCT00947596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine sulfate
Description: intramuscular injection
Study NCT02931383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg (Saxenda)
Study NCT02931383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide 3 mg placebo
Study NCT04372849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human nasal insulin
Description: single dose of 160 U of human insulin as nasal spray
Study NCT04372849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo solution as nasal spray
Study NCT03547726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: These patients will receive a formal physical therapy protocol by seeing a physical therapist in clinic.
Study NCT03547726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Rehab
Description: These patients will be provided with a list of actions NOT to perform and allowed to self rehabilitate. They will not see a physical therapist.
Study NCT02429375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat Plus Brentuximab Vedotin
Description: All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
Study NCT03544814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib combined with pemetrexed plus cisplatin
Description: Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
Study NCT03698513 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for BMS-986177)
Description: BMS-986177 placebo match capsule
Study NCT03698513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel tablet
Study NCT03698513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel tablet
Study NCT03698513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin tablet
Study NCT03544814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first icotinib and then pemetrexed plus cisplatin
Description: Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
Study NCT03475134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIL
Description: Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
Study NCT03698513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin tablet
Study NCT03314441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
Study NCT02671695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spirulina
Description: Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
Study NCT02671695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine in a dose of 5 mg/day orally for 3 months
Study NCT01072539 — intervention group
Intervention type: DRUG
Intervention: tigecycline
Description: As prescribed by physician in usual clinical practice
Study NCT02731118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salovum
Description: AF-enriched egg yolk
Study NCT02731118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: egg yolk
Study NCT00999856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOMIS and Photometer
Description: Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
Study NCT01597960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
Study NCT00999856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOMIS and Photometer
Description: An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
Study NCT00999856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOMIS and Photometer
Description: Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
Study NCT00999856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOMIS and Photometer
Description: After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
Study NCT00999856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GOMIS and Photometer
Description: The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
Study NCT00123916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benznidazole
Description: Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
Study NCT03316794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-005
Description: intravenous
Study NCT00533013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Management of heart failure is provided by primary practitioners and consultant cardiologists
Study NCT00123916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
Study NCT00533013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disease Management and Tele-Monitoring
Description: Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
Study NCT02545751 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
Study NCT02545751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
Study NCT03514251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The suture marks the location of the parathyroid gland
Description: When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker. Vascular protection.
Study NCT03829917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine and Paromomycin
Description: 28 days of miltefosine plus 28 days of Paromomycin cream
Study NCT03829917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: miltefosine
Description: 28 days of miltefosine
Study NCT03829917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paromomycin
Description: 28 days of paromomycin creaam
Study NCT01563991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal fluid volume
Description: Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total
Study NCT01563991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced fluid volume
Description: Subject receives 80 cc/ hr LR during the peri-operative period
Study NCT00316316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interviewing plus exposure and response prevention (MI plus EX/RP)
Description: Participants will receive 18 sessions of MI plus EX/RP.
Study NCT00316316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and response prevention (EX/RP)
Description: Participants will receive 18 sessions of EX/RP.